Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
04/06/2025 12:13
June 4 (Reuters) - Vigil Neuroscience Inc VIGL.O: VIGIL NEUROSCIENCE PROVIDES UPDATE ON ILUZANEBART PHASE 2 IGNITE TRIAL IN ALSP VIGIL NEUROSCIENCE INC - ILUZANEBART SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE VIGIL NEUROSCIENCE INC - PHASE 2 LONG-TERM EXTENSION STUDY DISCONTINUED VIGIL NEUROSCIENCE INC - PHASE 2 IGNITE TRIAL SHOWS NO BENEFICIAL EFFECTS Source text: ID:nGNXbqMz4d Further company coverage: VIGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions